Lv1
40 积分 2024-08-08 加入
Clarifying intrinsic efficacy, partial agonism, and full agonism: moving beyond efficacy and affinity towards ligand-directed signalling. Comment on Br J Anaesth 2024; 132: 431–2
1个月前
已关闭
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
2个月前
已完结
Clinical development times for innovative drugs
4个月前
已完结
What matters most in commercial success: first-in-class or best-in-class?
4个月前
已完结
Chinese innovative drug R&D trends in 2024
4个月前
已完结
Different Development Strategies Affecting Japan’s Drug lag between Japan-Based and Foreign-Based Companies
5个月前
已完结
Investigating the origins of recent pharmaceutical innovation
5个月前
已完结
Biopharma M&A flow picks up
5个月前
已完结
Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
6个月前
已完结
皖公网安备34019202002308
